Status:
COMPLETED
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Lead Sponsor:
Karolinska University Hospital
Collaborating Sponsors:
Meyer Children's Hospital IRCCS
Leiden University Medical Center
Conditions:
Hemophagocytic Lymphohistiocytosis
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE3
Brief Summary
Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.
Detailed Description
The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide additional therapy during this period as compared to in HLH-94.
Eligibility Criteria
Inclusion
- Patients who fulfil the diagnostic criteria of HLH.
Exclusion
- Prior cytotoxic or cyclosporin treatment for HLH.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
368 Patients enrolled
Trial Details
Trial ID
NCT00426101
Start Date
January 1 2004
End Date
December 1 2017
Last Update
July 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childhood Cancer Research Unit, Karolinska Hospital
Stockholm, Sweden, S-171 76